FIELD: chemistry.
SUBSTANCE: disclosed are peptides which are isolated from the FOXM1 protein and are capable of activating cytotoxic (killer) human T cells by forming an antigen-presenting complex with a HLA-A2 molecule. Disclosed are compositions which contain the disclosed peptides, use of a peptide to produce an agent for inducing cancer immunity, treating and preventing cancer, and for producing antibodies which selectivity bind the disclosed peptides. The invention describes an exosome and an isolated antigen-presenting cell, which present a complex of the disclosed peptide with a HLA-A2 molecule, for inducing cytotoxic T cells, methods of inducing a antigen-presenting cell and a cytotoxic T cell, as well as a method of damaging FOXM1 and HLA-A2 expressing cells.
EFFECT: invention can further be used in treating tumours that are characterised by high FOXM1 expression.
14 cl, 2 ex, 1 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| CDCA1 PEPTIDE AND PHARMACEUTICAL DRUG CONTAINING IT | 2008 |
|
RU2486195C2 |
| TOPK PEPTIDES AND THEIR VACCINES | 2012 |
|
RU2633503C2 |
| SPARC-DERIVATIVE ANTIGENIC PEPTIDES CAUSING TUMOUR REJECTION AND MEDICATIONS CONTAINING SUCH PEPTIDES | 2007 |
|
RU2451521C2 |
| UBE2T PEPTIDE AND VACCINES CONTAINING THE SAME | 2013 |
|
RU2663350C2 |
| PEPTIDE DERIVED FROM FOXM1, AND INCLUDING ITS VACCINE | 2016 |
|
RU2738418C2 |
| KNTC2 PEPTIDES AND VACCINES CONTAINING THE SAME | 2014 |
|
RU2671395C2 |
| TUMOUR-REJECTING GLYPICAN-3 (GPC3)-DERIVATIVE ANTIGENIC PEPTIDES USED FOR HLA-A2-POSITIVE PATIENTS, AND PHARMACEUTICAL PRODUCT CONTAINING SAID PEPTIDES | 2006 |
|
RU2395519C2 |
| TTK PEPTIDES AND VACCINES CONTAINING THEM | 2010 |
|
RU2531348C2 |
| EPITOPIC PEPTIDES RAB6KIFL/KIF20A AND VACCINES CONTAINING THEM | 2009 |
|
RU2532105C2 |
| CDH3-PEPTIDE AND DRUG PREPARATION CONTAINING IT | 2008 |
|
RU2483078C2 |
